Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection. Materials and Methods This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values. Results Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis. Conclusion This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.
Abstract
Purpose Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection. Materials and Methods This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values. Results Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis. Conclusion This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.
참고문헌 (32)
- Sasako M, "D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer", N Engl J Med, 359, pp.453~462 (2008)
- Zhang CD, "Prognostic significance of distal subtotal gastrectomy with standard D2 and extended D2 lymphadenectomy for locally advanced gastric cancer", Sci Rep, 5, pp.17273~ (2015)
- Lee HK, "Influence of the number of lymph nodes examined on staging of gastric cancer", Br J Surg, 88, pp.1408~1412 (2001)
- Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
- Noh SH, "Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : 5-year follow-up of an openlabel, randomised phase 3 trial", Lancet Oncol, 15, pp.1389~1396 (2014)
- Bang YJ, "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : a phase 3 open-label, randomised controlled trial", Lancet, 379, pp.315~321 (2012)
- Takezawa K, "Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer", Br J Cancer, 104, pp.1594~1601 (2011)
- Sasako M, "Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II", III gastric cancer, 2015, pp.18, 538~548
- Jiang J, "ERCC1expression as a prognostic and predictive factor in patients with non-small cell lung cancer : a meta-analysis", Mol Biol Rep, 39, pp.6933~6942 (2012)
- Olaussen KA, "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy", N Engl J Med, 355, pp.983~991 (2006)
- Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
- Muro K, "Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012) : a multicentre, openlabel, phase 1b trial", Lancet Oncol, 17, pp.717~726 (2016)
- Gao Q, "Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma", Clin Cancer Res, 15, pp.971~979 (2009)
- Massi D, "PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteris-tics", Ann Oncol, 25, pp.2433~2442 (2014)
- Boger C, "PD-L1 is an independent prognostic predictor in gastric cancer of Western patients", Oncotarget, 7, pp.24269~24283 (2016)
- Chang H, "Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group", Oncotarget, 7, pp.80426~80434 (2016)
- Kwon MJ, "Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection", Oncotarget, 8, pp.82399~82414 (2017)
- Wu Y, "PD-1 and PDL1co-expression predicts favorable prognosis in gastric cancer", Oncotarget, 8, pp.64066~64082 (2017)
- McCarty KS Jr, "Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies", Arch Pathol Lab Med, 109, pp.716~721 (1985)
- Hirsch FR, "PD-L1 immunohistochemistry assays for lung cancer : results from phase 1 of the Blueprint PD-L1 IHC assay comparison project", J Thorac Oncol, 12, pp.208~222 (2017)
- 정규원, "Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study", Cancer Research and Treatment, 45(3), pp.162~171 (2013), 대한암학회
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
- Ribelles N, "A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression", Curr Drug Metab, 9, pp.336~343 (2008)
- Gurubhagavatula S, "XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy", J Clin Oncol, 22, pp.2594~2601 (2004)
- De Dosso S, "ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy", Cancer Chemother Pharmacol, 72, pp.159~165 (2013)
- Wang J, "Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer", Chin J Cancer Res, 26, pp.323~330 (2014)
- Grau JJ, "Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur", Oncology, 66, pp.226~233 (2004)
- Choi J, "Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection", Br J Cancer, 84, pp.186~192 (2001)
- Kang YK, "Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.2461~2471 (2017)